{"entity":{"id":"nct06312176","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","aka":[],"tldr":"A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Capecitabine and Doxorubicin in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010). ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 1200 participants. Primary completion is estimated at 2027-07-11. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin. Registered primary measures: Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC); PFS (Sacituzumab tirumotecan + pembrolizumab versus TPC).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06312176","url":"https://clinicaltrials.gov/study/NCT06312176"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc","checkpoint-inhibitor","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["sacituzumab-tirumotecan","pembrolizumab","capecitabine","doxorubicin"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 1200 participants. Primary completion is estimated at 2027-07-11. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06312176","phase":"3","setting":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06312176","source":"https://clinicaltrials.gov/study/NCT06312176","fetchedAt":"2026-10-07T16:54:32.196Z","studySha256":"6020aa53c93e6d987d79d85cff2bd11a929c9d741e99ffd4dcba136eec7c164f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1200,"enrolmentType":"ESTIMATED","siteCount":259,"recruitingSiteCount":190,"countries":["Argentina","Australia","Belgium","Brazil","Canada","Chile","Colombia","Costa Rica","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Peru","Philippines","Poland","Portugal","Puerto Rico","Romania","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-04-14","startedType":"actual","enrolled":1200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06312176/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}